Tianjin CanSino Biologics
Yunli XU was appointed as vice president of vaccine research and development in 2020. He is in charge of the R&D of viral and genetic products, as well as the construction and management of GMP pilot plants. With over 30 years of experience in the field of biotechnology, Mr. Xu has led multiple pre-clinical trial projects on gene therapy and is proficient in GMP pilot plant design, sample preparation and manufacturing verification. He used to serve as director in the NIP Pharm and general manager in Vector Gene Technology Company Ltd., Mr. Xu holds a degree of biology from Wuhan University and a degree of genetic engineering and molecular biology from Otsuka Pharmaceutical Co., Ltd.
This person is not in any offices
Tianjin CanSino Biologics
1 followers
Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.